Samuel J. Klempner, MD, on Advanced Gastric/GEJ Cancer: Zolbetuximab Plus mFOLFOX6 and Nivolumab
2026 ASCO GI
Samuel J. Klempner, MD, of Massachusetts General Hospital, discusses results from the phase II ILUSTRO trial, which evaluated the combination of the anti-CLDN18.2 antibody zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive; HER2-negative; locally advanced, unresectable, or metastatic gastric/gastroesophageal junction (GEJ) adenocarcinoma (Abstract LBA284).
The ASCO Post Staff
Dina Ioffe, MD, of Fox Chase Cancer Center, describes the results of an analysis that sought to determine how race/ethnicity, insurance status, and socioeconomic status may affect patterns of systemic treatment for metastatic hepatocellular carcinoma (HCC) (Abstract 489).
The ASCO Post Staff
Marcel Verheij, MD, PhD, of Radboud University Medical Center, presents findings from the phase II CRITICS-II trial, which compared three preoperative regimens while omitting adjuvant treatment among patients with nonmetastatic resectable gastric cancer: chemotherapy, chemotherapy followed by chemoradiotherapy, and chemoradiotherapy (Abstract 283).
The ASCO Post Staff
Elizabeth Smyth, MD, of the Oxford NIHR Biomedical Research Centre, Churchill Hospital, presents findings from an analysis of the MATTERHORN trial, a phase III study that examined fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus durvalumab in patients with resectable gastric/gastroesophageal junction cancer. Dr. Smyth discusses rates of FLOT discontinuation along with event-free survival based on FLOT completion status in the trial (Abstract 343).
The ASCO Post Staff
Stephen Lam Chan, MD, FRCP, MRCP, of the Hong Kong Cancer Institute, The Chinese University of Hong Kong, discusses findings from the phase III KEYNOTE-937 trial, which evaluated the efficacy and safety of pembrolizumab vs placebo as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who had undergone surgical resection or local ablation with curative intent (Abstract 477).
The ASCO Post Staff
Elena Elimova, MD, of Princess Margaret Cancer Centre, presents findings from the primary analysis of the phase III HERIZON-GEA-01 trial, which evaluated zanidatamab, a dual HER2-targeted bispecific antibody, plus chemotherapy with or without the PD-1 inhibitor tislelizumab vs trastuzumab plus chemotherapy as first line-regimens for HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (Abstract LBA285).
